SGLT2 inhibitors × cardiovascular events

TrialCirculation2018

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.

Karin Rådholm et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 142 people · 2018

Randomised comparison

Probably reduced cardiovascular events

−22%−33% to −9%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.78, 95% CI 0.67–0.91

Randomised comparison

Probably reduced cardiovascular events

−33%−48% to −13%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.67, 95% CI 0.52–0.87

Randomised comparison

Probably reduced cardiovascular events

−30%−45% to −11%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.70, 95% CI 0.55–0.89

Not counted

Probably reduced cardiovascular events

−39%−54% to −20%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.46–0.80

+1 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.91), as was fatal or hospitalized HF (HR, 0.70; 95% CI, 0.55-0.89) and

patients with a prior history of HF (HR, 0.61; 95% CI, 0.46-0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72-1.06; P

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.780.67–0.91
Cardiovascular events
HR 0.670.52–0.87
Cardiovascular events
HR 0.700.55–0.89
Cardiovascular events
HR 0.610.46–0.80
Cardiovascular events
HR 0.870.72–1.06
SGLT2 inhibitorsCardiovascular events

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this paperthis papermore certainless certain
1 / 6

213 papers cite itlatest 60 shown

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

4 trials

Full record →Abstract, authors, funding and every citing paper · PMID 29526832